Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.57 |
| ▸ | DRD3 | P35462 | 6/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3845415 | 0.88 | DRD2 (0.56) | DRD2DRD3HTR7DRD4 | |
| SCHEMBL3851239 | 0.88 | DRD2 (0.64) | DRD2DRD3DRD4 | |
| SCHEMBL3849066 | 0.87 | DRD2 (0.65) | DRD2DRD3HTR7 | |
| SCHEMBL3847014 | 0.87 | DRD2 (0.59) | DRD2DRD3HTR7DRD4 | |
| SCHEMBL3844060 | 0.87 | DRD2 (0.66) | DRD2DRD3DRD4 | |
| SCHEMBL4501250 | 0.86 | DRD2 (0.61) | DRD2DRD3 | |
| SCHEMBL3844447 | 0.85 | DRD2 (0.56) | DRD2DRD3MAPT | |
| SCHEMBL3844707 | 0.84 | DRD2 (0.55) | DRD2DRD3DRD4 | |
| SCHEMBL4487040 | 0.83 | DRD2 (0.54) | DRD2DRD3HTR7DRD4MAPT | |
| SCHEMBL3848125 | 0.82 | DRD2 (0.51) | DRD2DRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | claimed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | claimed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | DRD2 4/4885DRD3 1/4885HTR7 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.